Summary & Overview
HCPCS Level II J0515: Benztropine Mesylate Injection, 1 mg
HCPCS Level II code J0515 represents an injectable dose of benztropine mesylate billed per 1 mg. Benztropine is an anticholinergic medication commonly used for management of extrapyramidal symptoms, acute dystonia, and certain movement disorder adjunctive therapy. As an HCPCS Level II code, J0515 is applied to record the drug product and units administered in outpatient, emergency, or inpatient settings where injectable medications are provided.
This publication covers national payer approaches for Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing context, common modifiers, and practical service-line implications. The analysis highlights how the code aligns with medication administration workflows, unit reporting considerations, and where clinicians and billing teams should confirm coverage rules.
The report includes benchmark-oriented content and policy-relevant notes to inform coding accuracy and reimbursement alignment. It also outlines typical clinical scenarios for use of benztropine injection and clarifies where to look for payer-specific billing rules and preauthorization requirements. Data not available in the input is explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code J0515 designates an injection of benztropine mesylate, per 1 mg. This code is used to report individual milligram units of benztropine provided as an injectable medication.
Service type: Medication administration / injectable anticholinergic therapy
Typical site of service: Outpatient clinic, emergency department, inpatient facility, or other settings where injectable medications are administered
Data not available in the input for additional fields such as associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent presenting to an outpatient infusion clinic, emergency department, or psychiatric facility with acute extrapyramidal symptoms (EPS) such as acute dystonic reaction, severe parkinsonism from antipsychotic therapy, or medication-induced akathisia. The clinician orders J0515 (benztropine mesylate injection, per 1 mg) to rapidly reverse or mitigate EPS. Workflow: assessment of vital signs and neurologic status; review of current medications (antipsychotics, antiemetics); informed consent and allergy check; preparation of appropriate dose (commonly 1–2 mg IM or slow IV push depending on severity and provider preference); administration with monitoring for anticholinergic side effects (tachycardia, dry mouth, urinary retention); documentation of indication, dose (units billed as mg), route, lot number, and post-administration response. Typical sites of service include outpatient infusion centers, emergency departments, inpatient hospital units, and behavioral health facilities.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Patient had the procedure performed | Use when the service was actually performed as scheduled |
22 |